Loading...

Haleon plc

HLN•NYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$9.65
$0.12(1.26%)

Haleon plc (HLN) AI-Powered Stock Analysis

See how Haleon plc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

Haleon plc (HLN) Stock Overall Grade

Haleon plc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

B

Good

Grade Breakdown by Metric

See how each financial and market factor contributes to Haleon plc's overall stock rating.

Forecast

B

Score

62/100

Financial Growth

C

Score

40/100

Fundamental Growth

B+

Score

73/100

Key Ratios

B

Score

65/100

Sector Comparison

B+

Score

75/100

Industry Comparison

B+

Score

75/100

S&P 500 Benchmark

A

Score

85/100

Analyst Consensus

C+

Score

50/100

Haleon plc (HLN) AI-Powered Stock Analysis

This asset demonstrates Good performance with an overall Forecast Score of 62/100 (B), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (73/100, B+) highlight its stability, while Key Ratios (65/100, B) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.

Component Analysis Explained

Understand the key factors behind each Haleon plc stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions

;